Marc, Author at Inoviem

Services

Services

Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens. All the platforms and services are label free with no modification of the original molecules.

Understand the mode of action of your compound

Identify and validate drug-target engagement

Lead compound optimization

Patient stratification and biomarkers discovery

Indication prioritization

Identify biomarkers and clinical pharmacology

SPR services

MoA Screening
Technology

Technology

Inoviem provides breakthrough protein technologies for each phase of the drug development process.
One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

Preclinical

How to best identify the Mode of Action of your compound

Read more

From preclinical to clinical

Ensure Phase II study and success of your drug candidate in Phase III

Read more

Clinical

Successfully identify the cohort of patients who will respond to your therapy

Read more
Expertise

Our expertise in translational pharmacology

Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

Translational pharmacology expertise

Pre-clinical to clinical phases

Read more

Our innovative approach

Biomarkers, patient and therapeutic window

Read more

Advantages of approach

Save time and money

Read more

How we work with clients

Tailored methodologies and technologies

Read more
Knowledge centre
About us
About us
Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

Our mission

Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

Read more

Our team

Management team

Scientific board

Supervisory board & investors

Read more
Contact us

Webinar – NPOT® analysis & Interactomics

Webinar – High molecular weight compounds target identification

Webinar – Proteins / peptides target identification

Join us on coming congress!

Webinar – Small molecule target identification

Webinar – Drug target identification technologies

How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?

Description

Evodiamine as a Macrophage Cholesterol Efflux Enhancer: Interactome Analysis Reveals ABCA1 to be a Direct Binding Target

Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_ga_61RXK9ZCWR	2 years	This cookie is installed by Google Analytics.

Others

Author: Marc

Webinar – NPOT® analysis & Interactomics

Webinar – High molecular weight compounds target identification

Webinar – Proteins / peptides target identification

Join us on coming congress!

Webinar – Small molecule target identification

Webinar – Drug target identification technologies

How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?

Evodiamine as a Macrophage Cholesterol Efflux Enhancer: Interactome Analysis Reveals ABCA1 to be a Direct Binding Target

Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients

SERVICES

EXPERTISE

TECHNOLOGY

RESOURCES

ABOUT US

PRIVACY POLICY